Core Insights - Prestige Consumer Healthcare Inc. reported strong financial results for the fourth quarter and fiscal year ended March 31, 2025, with record sales driven by international business strength and eCommerce growth [2][3][6] - The company achieved a 7.0% increase in fourth-quarter revenues to $296.5 million compared to $277.0 million in the same quarter of the previous year, with a 7.9% organic revenue growth [3][8] - Fiscal year 2025 revenues totaled $1,137.8 million, reflecting a 1.1% increase from $1,125.4 million in fiscal year 2024, with notable growth in the Gastrointestinal category [6][7] Financial Performance - Fourth-quarter net income was reported at $50.1 million, up from $49.5 million in the prior year, with diluted earnings per share (EPS) of $1.00 compared to $0.98 [4][7] - For fiscal year 2025, net income reached $214.6 million, an increase from $209.3 million in the previous year, with diluted EPS of $4.29 compared to $4.17 [7][8] - Non-GAAP adjusted net income for the fourth quarter was $65.9 million, up from $51.4 million in the prior year, leading to an adjusted diluted EPS of $1.32 compared to $1.02 [4][8] Segment Performance - North American OTC Healthcare segment revenues for the fourth quarter were $248.9 million, a 7.7% increase from $231.1 million in the prior year, driven by growth in GI and Women's Health categories [13][14] - International OTC Healthcare segment revenues for the fourth quarter were $47.6 million, a 3.7% increase from $45.9 million in the prior year, with strong performance from the Hydralyte brand [15][16] Cash Flow and Capital Allocation - The company generated $61.8 million in net cash from operating activities in the fourth quarter, down from $66.9 million in the prior year, with non-GAAP free cash flow of $58.4 million compared to $63.8 million [10][11] - For fiscal year 2025, net cash provided by operating activities was $251.5 million, slightly up from $248.9 million in the previous year, with non-GAAP free cash flow increasing by 1.6% to $243.3 million [11][12] Outlook - The company anticipates organic revenue growth of approximately 1% to 2% and diluted EPS in the range of $4.70 to $4.82 for fiscal year 2026, despite facing inflationary pressures from tariffs [17][18] - The initial revenue outlook for fiscal 2026 is projected between $1,140 million and $1,155 million, with free cash flow expected to exceed $245 million [18]

Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 8, 2025-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which delivered another year of consistent sales and earnings per share growth. The record fourth quarter sales performance exceeded our expectations, driven by continued Internat ...

Core Insights - Prestige Consumer Healthcare Inc. reported strong financial results for the fourth quarter and fiscal year ended March 31, 2025, with record sales driven by international business strength and eCommerce growth [2][3][6]. Financial Performance - Fourth quarter revenues reached $296.5 million, a 7.0% increase from $277.0 million in the same quarter of the previous year, with a 7.9% increase when excluding foreign currency impacts [3][6]. - Fiscal year 2025 revenues totaled $1,137.8 million, up 1.1% from $1,125.4 million in fiscal year 2024, with a 1.2% increase excluding foreign currency effects [6][7]. - Net income for the fourth quarter was $50.1 million, compared to $49.5 million in the prior year, while diluted earnings per share (EPS) increased to $1.00 from $0.98 [4][7]. - For fiscal year 2025, reported net income was $214.6 million, up from $209.3 million, with diluted EPS rising to $4.29 from $4.17 [7][8]. Segment Performance - North American OTC Healthcare segment revenues for Q4 were $248.9 million, a 7.7% increase from $231.1 million in the prior year, driven by growth in GI and Women's Health categories [13][14]. - International OTC Healthcare segment revenues for Q4 were $47.6 million, a 3.7% increase from $45.9 million, with significant growth attributed to the Hydralyte brand [15][16]. Cash Flow and Capital Allocation - The company generated $61.8 million in net cash from operating activities in Q4, down from $66.9 million in the prior year, while non-GAAP free cash flow was $58.4 million, a decrease from $63.8 million [10][11]. - For the fiscal year, net cash provided by operating activities was $251.5 million, slightly up from $248.9 million, with non-GAAP free cash flow increasing by 1.6% to $243.3 million [11][12]. Shareholder Returns and Debt Management - The company repurchased approximately 0.7 million shares for about $51.5 million during fiscal 2025, reducing net debt to approximately $0.9 billion, resulting in a leverage ratio of 2.4x [12][18]. - The company plans to maintain a disciplined capital allocation approach, focusing on share repurchases, M&A, and deleveraging [2][8]. Fiscal 2026 Outlook - The company anticipates organic revenue growth of approximately 1% to 2% and diluted EPS in the range of $4.70 to $4.82 for fiscal 2026, despite facing inflationary headwinds from tariffs [17][18].

Access to the live question and answer session may be obtained by calling the operator at (289) 514-5100 / (800) 717-1738 (Conference ID: 07724) up to ten minutes prior to the scheduled start time. For those who are unable to participate, a recording of the question and answer session will be available through to 11:59 p.m. Toronto time on Saturday, June 7, 2025 at (289) 819-1325 / (888) 660-6264 (passcode: 07724#). Alternatively, a recording of the question and answer session will be available at the Compa ...

Trade Policy Impact - The United States has implemented new tariffs, with a 10% baseline tariff on most imports and up to 145% on Chinese goods, significantly affecting global trade dynamics [1] - The elimination of the "de minimis" exemption for shipments under $800 impacts low-cost Chinese e-commerce platforms like Temu and Shein [1] - China has responded by suspending exports of critical minerals, escalating the trade conflict and increasing uncertainty in global markets [1] Economic Consequences - Previous tariffs from 2018 to 2020 resulted in over $80 billion in additional costs for American businesses and consumers, raising concerns about price increases and margin compression across industries [2] - The reintroduction of tariffs in 2025 has raised alarms in the corporate sector, particularly regarding the implementation timeline and potential retaliatory measures from trade partners like China [2] Pharmaceutical Sector - The U.S. government is preparing to impose tariffs on select pharmaceutical imports from countries like China and India, raising concerns about increased costs and supply chain disruptions [3] - Pharmaceutical companies, reliant on international manufacturing, are particularly vulnerable to trade disruptions, leading to a cautious sentiment in the industry [3] Medical Device Sector - The medical device sector is identified as a strong investment opportunity, driven by technological advancements, demographic trends, and increasing demand for healthcare solutions [4] - The global medical devices market was valued at $518.46 billion in 2023 and is projected to grow to over $886.80 billion by 2032, with a CAGR of 6.3% [5] Investment Opportunities - Amid tariff uncertainties, investors are focusing on undervalued stocks with strong balance sheets and resilient performance, particularly in the medical device sector [6] - Promising undervalued stocks for 2025 include Cencora, Inc. (COR), Hims & Hers Health (HIMS), and Prestige Consumer (PBH) [6] Cencora, Inc. - Cencora is a major pharmaceutical services company with a diverse portfolio, including biologics and complex injectables [7] - The company has launched Accelerate Pharmacy Solutions to optimize operations for healthcare customers and has acquired Retina Consultants of America to enhance its specialty leadership [8] - Cencora's stock trades at a P/S ratio of 0.17, lower than the Medical Services market's 0.40, with an expected 11.6% growth in 2025 earnings [9] Hims & Hers Health - Hims & Hers Health offers subscription-based telehealth services and aims to simplify healthcare through a digital-first platform [10] - The company has a P/S ratio of 2.47, discounted compared to the industry's 4.03, with a projected 58% growth in 2025 earnings [11] Prestige Consumer - Prestige Consumer provides over-the-counter healthcare products and has a strong presence across various retail channels [12] - The gastrointestinal product category is a significant growth driver, representing nearly one-fifth of North American sales [13] - The stock trades at a P/S ratio of 3.43, lower than the industry's 5.32, with a recent earnings surprise of 5.17% [16]

Core Viewpoint - Prestige Consumer Healthcare Inc. is set to release its fiscal 2025 fourth quarter and year-end earnings on May 8, 2025, before market opening, followed by a conference call at 8:30 a.m. ET to discuss the results [1]. Company Overview - Prestige Consumer Healthcare Inc. markets, sells, manufactures, and distributes a wide range of consumer healthcare products across the U.S., Canada, Australia, and other international markets [4]. - The company's diverse portfolio includes well-known brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon® in Canada, Hydralyte®, and the Fess® line of products in Australia [4].

Core Insights - Prestige Consumer Healthcare (PBH) is focused on brand building and portfolio expansion through strategic acquisitions, which is expected to drive growth in upcoming quarters [1][5] - The company has experienced a share price increase of 19.3% over the past year, outperforming the industry and S&P 500 [1] Company Overview - PBH has a market capitalization of $4.17 billion and reported an earnings surprise of 5.17% in the last quarter [2] - The earnings yield for PBH stands at 5.4%, significantly higher than the industry's 0.3% [2] Growth Drivers - The strength of PBH's diversified portfolio, which includes well-recognized consumer brands, has contributed to sales growth and long-term profitability, with core brands generating nearly 58.6% of total revenues in fiscal 2024 [3] - The gastrointestinal (GI) product category is a significant contributor, accounting for nearly 20% of North American sales, with brands like Dramamine, Fleet, and Gaviscon leading the category [4] - The company is also seeing growth in the e-commerce channel, reflecting a long-term trend towards online purchases [4] Strategic Acquisitions - PBH has expanded its brand portfolio through both organic growth and acquisitions, including the purchase of TheraTears and other over-the-counter brands from Akorn Operating Company LLC, as well as Hydralyte from Hydration Pharmaceuticals Trust [5] Financial Concerns - As of the end of the fiscal third quarter, PBH had a long-term debt of $996 million and cash and cash equivalents of $51 million, with a debt-to-capital ratio of 35.8% [7] - The company generated approximately 14.8% of its fiscal 2024 revenues from international business, making it susceptible to currency fluctuations [9] Earnings Estimates - The Zacks Consensus Estimate for PBH's fiscal 2025 earnings per share has increased by 0.4% to $4.52, with revenue estimates at $1.13 billion, reflecting a 0.5% increase from the previous year [10]

Core Viewpoint - Premium Brands Holdings Corporation has announced a bought-deal offering of $150 million in convertible unsecured subordinated debentures, with potential total gross proceeds of $172.5 million if the over-allotment option is exercised [1][2][3] Group 1: Offering Details - The company will issue $150,000,000 aggregate principal amount of convertible unsecured subordinated debentures at a price of $1,000 per debenture [1] - An over-allotment option allows underwriters to purchase an additional $22,500,000 in debentures, potentially raising total gross proceeds to $172,500,000 [1] - The closing of the offering is expected around March 19, 2025, subject to regulatory approvals [6] Group 2: Use of Proceeds - Net proceeds from the offering will be used to repay existing indebtedness under credit facilities, which will then be available for the redemption of the 4.65% debentures, future acquisitions, capital projects, and general corporate purposes [3] Group 3: Debenture Terms - The debentures will bear interest at 5.50% per annum, payable semi-annually, with a maturity date of March 31, 2030 [4] - Holders can convert the debentures into common shares at a conversion price of $126.15 per share, equating to 7.9271 shares for each $1,000 principal amount [5]

Financial Data and Key Metrics Changes - Net sales for Q3 2025 reached $290 million, an increase of nearly 3% year-over-year, exceeding forecasts [8][19] - Earnings per share (EPS) increased by 15% to a record $1.22, driven by strong sales growth and lower interest expenses [9][20] - Free cash flow for the first nine months was $184.9 million, up 5% year-over-year, with a full-year outlook of $240 million or more [27][32] Business Line Data and Key Metrics Changes - The GI category, which includes brands like Dramamine, Fleet, and Gaviscon, represents nearly one-fifth of North American sales, showing solid mid-single-digit growth over the last three years [11][16] - International segment sales grew approximately 8% excluding foreign exchange, with Hydralyte being a key contributor [19][63] - The Cough & Cold category saw a decline, expected to be flat to down slightly for the year, impacting overall sales [44][46] Market Data and Key Metrics Changes - E-commerce sales continued to show double-digit year-over-year growth, indicating a long-term trend towards higher online purchasing [22] - The North American segment experienced broad-based growth, with notable increases in the GI category brands, partially offset by lower Cough & Cold sales [19][21] Company Strategy and Development Direction - The company is focused on capital deployment options to enhance shareholder value, including opportunistic share repurchases and potential M&A activities [10][29] - Management anticipates revenue for fiscal 2025 to be between $1.128 billion and $1.132 billion, with an organic revenue growth forecast of approximately 1% [30][32] - The company is well-positioned to manage inflation and tariff changes due to its diversified supply base and strong market share [24][49] Management's Comments on Operating Environment and Future Outlook - Management noted heightened uncertainty in the business environment due to supply chain constraints and inflation, but remains optimistic about the company's performance [5][30] - The company expects to see gradual improvements in sales for Clear Eyes as production levels increase and additional suppliers are added [37][56] - Management expressed confidence in the business momentum heading into fiscal 2026, with record sales and EPS reported [41][72] Other Important Information - The company reduced its variable term loan debt balance to zero and improved its leverage ratio to 2.5x [10][28] - Advertising and marketing expenses were 14.1% of sales for the first nine months, with expectations for an increase in dollars compared to the prior year [25] Q&A Session Summary Question: Recovery expectations for Clear Eyes - Management indicated that production levels for Clear Eyes were in line with expectations, with sales slightly ahead due to timing differences [36] Question: Clarity on Q4 gross margin expectations - Management explained that the anticipated gross margin increase in Q4 is driven by the timing of cost-saving initiatives [39] Question: Inventory levels in the Cold & Cough category - Management noted that the Cold & Cough category is not a significant part of their portfolio, and they do not expect a substantial increase in reorder rates [44][46] Question: Exposure to tariffs - Management stated that while they monitor tariff implications, the majority of manufacturing is in the U.S., providing a strategic advantage [49] Question: Promotional intensity for Clear Eyes - Management confirmed that Clear Eyes remains a leading brand, and they do not anticipate changes in promotional activity as they regain shelf space [54] Question: Future plans for Hydralyte - Management discussed the long-term brand building strategy for Hydralyte, emphasizing a slow build in new markets [58] Question: International growth outside Hydralyte - Management highlighted strong growth across various brands in the care business, not limited to Hydralyte [62] Question: Expansion into oral laxatives for Fleet - Management confirmed the launch of constipation-related products under the Fleet brand, connecting with consumers based on the brand's heritage [68] Question: Free cash flow guidance - Management maintained the free cash flow guidance of $240 million or more, feeling positive about cash flow performance [76] Question: Appetite for acquisitions - Management expressed a healthy appetite for M&A opportunities, remaining disciplined in their approach [81]

Revenue Performance - Total revenues for the three months ended December 31, 2024 were $290.3 million, an increase of $7.6 million, or 2.7%, compared to the same period in 2023[94]. - Total revenues for the nine months ended December 31, 2024 were $841.2 million, a decrease of $7.1 million, or 0.8%, compared to the same period in 2023[110]. - North American OTC Healthcare segment revenues increased by $2.4 million, or 1.0%, primarily due to growth in the Gastrointestinal and Dermatologicals categories[95]. - North American OTC Healthcare segment revenues decreased by $16.1 million, or 2.2%, primarily due to declines in Cough & Cold, Women's Health, and Oral Care categories[112]. - International OTC Healthcare segment revenues increased by $5.2 million, or 11.3%, mainly driven by sales growth in the Gastrointestinal category[96]. - International OTC Healthcare segment revenues increased by $8.9 million, or 7.4%, mainly driven by growth in Gastrointestinal and Dermatologicals categories[113]. Profitability Metrics - Gross profit for the three months ended December 31, 2024 increased by $3.1 million, or 2.0%, but gross profit margin decreased to 55.5% from 55.9% due to increased supply chain costs[98]. - Gross profit for the nine months ended December 31, 2024 decreased by $8.2 million, or 1.7%, with gross profit margin declining to 55.2% from 55.7%[114]. - Contribution margin for the North American OTC Healthcare segment increased by $3.3 million, or 3.4%, with a margin of 41.8%, up from 40.8% in the prior year[103]. - Contribution margin for the North American OTC Healthcare segment decreased by $12.8 million, or 4.2%, to 40.8%[120]. - Contribution margin for the International OTC Healthcare segment increased by $1.3 million, or 6.0%, but margin decreased to 45.2% from 47.5% due to higher advertising and marketing expenses[104]. Expenses and Costs - General and administrative expenses were $26.2 million for the three months ended December 31, 2024, slightly up from $26.0 million in the same period of 2023[105]. - Depreciation and amortization expenses decreased to $5.0 million from $5.6 million, primarily due to certain intangible assets being fully depreciated[106]. - Interest expense, net decreased to $11.5 million from $16.6 million, with average indebtedness down to $1.0 billion from $1.3 billion[107]. - Interest expense, net decreased to $36.9 million for the nine months ended December 31, 2024, down from $51.9 million in the same period of 2023[124]. Cash Flow and Investments - Cash provided by operating activities was $189.7 million for the nine months ended December 31, 2024, an increase of $7.6 million compared to $182.0 million in 2023[128]. - Net cash used in investing activities was $14.0 million for the nine months ended December 31, 2024, compared to $5.1 million in 2023, primarily due to the acquisition of Hydralyte intellectual property[129]. - As of December 31, 2024, the company had cash and cash equivalents of $50.9 million, an increase of $4.4 million from March 31, 2024[127]. Debt and Compliance - The company repaid the balance of its 2012 Term B-5 Loans during the three months ended December 31, 2024[132]. - The company has a total debt maturity of $1,000 million, with $400 million maturing in 2028 and $600 million in 2031[133]. - The company must maintain a fixed charge ratio greater than 1.0 to 1.0, and it was in compliance with this requirement as of December 31, 2024[134]. - The company anticipates remaining in compliance with financial and restrictive covenants during the next twelve months[134]. Tax and Currency Exposure - The effective tax rate for the nine months ended December 31, 2024 was 21.8%, down from 23.4% in the same period of 2023[125]. - Approximately 18.2% of gross revenues for the three months ended December 31, 2024, were denominated in currencies other than the U.S. Dollar, compared to 17.0% for the same period in 2023[146]. - A hypothetical 10.0% adverse change in foreign currency exchange rates would have a pre-tax income impact of approximately $3.9 million for the three months ended December 31, 2024[147]. - The company is exposed to foreign currency exchange rate risks primarily with respect to the Canadian and Australian Dollars[146]. Accounting Policies - The company reported no material changes to its critical accounting policies during the nine months ended December 31, 2024[136]. - The company’s 2012 ABL Revolver had a zero balance at December 31, 2024, meaning none of its debt carried a variable rate of interest[145].